Substance- or Medication-Induced Psychosis with Government, Police, and Espionage Delusions

Introduction: The Architecture of Persecution

The clinical presentation of substance- or medication-induced psychotic disorder frequently manifests through highly structured, persecutory delusional frameworks. This psychological phenomenon, often conceptualized as the "architecture of persecution," describes a cognitive state wherein a person experiencing psychosis organizes disjointed, benign environmental stimuli into a cohesive, threatening, and systematized narrative. Within this framework, individuals frequently report being monitored, tracked, poisoned, or targeted for capture by government task forces, police officers, intelligence agencies, undercover agents, or advanced surveillance technologies such as aerial drones and hidden radio transmitters1. These complex persecutory delusions are rarely random; they represent the psychological sequelae of aberrant salience driven by profound neurochemical alterations. Specifically, dopaminergic and noradrenergic overdrive within the mesolimbic and prefrontal circuits strips the central nervous system of its capacity to filter irrelevant environmental noise3. When external substances or iatrogenic medications artificially elevate extracellular dopamine or antagonize inhibitory neurotransmission, benign cues—such as a parked utility vehicle, static on a telephone line, or a passing pedestrian—are imbued with intense, life-threatening significance5. The individual's cognitive architecture forces these hyper-salient cues into a logical, albeit psychotic, framework, often culminating in the unwavering belief in an orchestrated espionage or law enforcement operation aimed at their capture or demise. Evaluating, diagnosing, and managing these acute psychiatric presentations requires meticulous clinical acumen. Healthcare professionals must navigate complex diagnostic criteria, interpret highly nuanced toxicological data replete with cross-reactivities, differentiate transient substance-induced states from the prodrome of primary schizophrenia-spectrum illnesses, and formulate comprehensive acute stabilization and longitudinal treatment plans. Furthermore, clinical assessments must carefully untangle factual events—such as documented, routine law enforcement contact or legitimate legal difficulties—from the psychotic interpretations grafted onto those events. It is a fundamental clinical imperative to establish therapeutic rapport and ensure safety without ever validating or affirming unverified claims of surveillance, poisoning, or targeted persecution.

Diagnostic Frameworks: DSM-5-TR and ICD-11

The diagnostic boundaries for substance-induced psychosis are delineated by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) and the International Classification of Diseases, Eleventh Revision (ICD-11). Both frameworks aim to distinguish transient, chemically driven psychotic episodes from primary, independent psychiatric illnesses. However, they approach causality, temporal boundaries, and the philosophical underpinnings of dual diagnoses with subtle but critical differences.

DSM-5-TR Diagnostic Requirements

Under the DSM-5-TR, Substance/Medication-Induced Psychotic Disorder requires the presence of prominent delusions and/or hallucinations that develop during or soon after substance intoxication, substance withdrawal, or after exposure to a medication6. The physiological effects of the substance must be established through clinical assessment as the direct etiology of the symptoms. The diagnostic criteria demand the presence of one or both core symptoms (delusions or hallucinations) alongside concrete evidence from the history, physical examination, or laboratory findings establishing the temporal relationship6. A critical exclusion criterion is that the disturbance must not be better explained by an independent psychotic disorder, such as schizophrenia or schizoaffective disorder6. Evidence of an independent disorder includes psychotic symptoms that precede the onset of substance use, or symptoms that persist for a substantial period—typically defined as one month or longer—after the cessation of acute withdrawal or severe intoxication6. Furthermore, the psychotic symptoms must not occur exclusively during the course of a delirium6. The DSM-5-TR emphasizes specifying the context of the onset using specifiers such as "with onset during intoxication," "with onset during withdrawal," or "with onset after medication use"6. Clinicians are also instructed to record comorbid substance use disorders by adjusting the specific diagnostic code position. For instance, if a mild substance use disorder is comorbid, the clinician should record "mild \[substance\] use disorder with \[substance\]-induced psychotic disorder," utilizing quantitative assessments to rate current severity on a 5-point scale based on the presence of delusions, hallucinations, and abnormal psychomotor behavior6.

ICD-11 Diagnostic Requirements

The ICD-11 categorizes these conditions under Block 6C4, titled "Disorders due to substance use and addictive behaviours," which encompasses substance-induced psychosis alongside substance-induced mood and anxiety disorders9. While the ICD-11 aligns with the DSM-5-TR regarding the core presentation of hallucinations and delusions emerging during or shortly after intoxication or withdrawal, it introduces specific coding hierarchies for individual substances (e.g., 6C4C.6 for MDMA-induced psychotic disorder)11. A critical evolution in psychiatric epidemiology and nosology regarding the ICD-11 criteria is the ongoing debate surrounding causal inference. The ICD-11 relies heavily on a temporal relationship to establish that drug use is the primary, precipitating etiology of the psychosis9. However, modern psychiatric literature highlights that relying solely on a temporal relationship is a crude simplification of the comprehensive Bradford-Hill criteria for establishing causality9. Complex cases involving multi-year, chronic substance use present immense diagnostic challenges. If a patient presents with ongoing substance use and concurrent psychotic symptoms, the strict application of temporal criteria often defaults to a substance-induced diagnosis9. This default categorization is highly problematic, as it potentially ignores the complex interplay of genetic disposition, environmental stress, psychological trauma, and underlying primary mental disorders9. To address this diagnostic inadequacy, progressive clinical frameworks advocate for the recognition of dual diagnoses. Rather than subsuming a psychotic presentation entirely under a substance-induced code simply due to temporal overlap, clinicians are encouraged to diagnose both a harmful substance use disorder (e.g., ICD-11 code 6C41.10) and an independent primary psychotic disorder concurrently when the exact etiological boundary is indistinguishable or when clinical history suggests profound underlying vulnerability exacerbated by substance use10.

Comparison of Diagnostic Parameters

The Temporal Relationship: Intoxication, Withdrawal, and Medication Exposure

The temporal kinetics of substance-induced psychosis are inextricably linked to the pharmacodynamics, pharmacokinetics, and route of administration of the offending agent. Establishing a highly accurate timeline of ingestion, symptom onset, and symptom offset is the most critical component of diagnostic formulation and safety planning.

Onset During Intoxication

Psychosis emerging during acute intoxication is highly characteristic of central nervous system (CNS) stimulants, high-potency cannabis, and hallucinogens. In these scenarios, the rapid escalation of extracellular neurotransmitters—particularly dopamine in the striatum and mesolimbic pathways—triggers the acute psychotic state2. Symptoms typically arise within minutes to hours of ingestion, peaking concurrently with the substance's maximum serum or cerebrospinal fluid concentration2. The clinical presentation is marked by extreme arousal, tachycardia, and a sudden break with reality. As the substance is enzymatically metabolized and excreted through renal or biliary pathways, the psychotic symptoms gradually wane, typically resolving within hours to days depending on the biological half-life of the drug16. However, chronic, high-dose exposure—such as multi-day methamphetamine binges—can lead to prolonged neuroplastic changes, down-regulation of receptor densities, and persistent psychotic states that extend well beyond the clearance of the drug1.

Onset During Withdrawal

Psychotic symptoms precipitated by withdrawal represent a distinctly different physiological crisis, most commonly associated with severe, prolonged physical dependence on CNS depressants, such as alcohol, benzodiazepines, or other sedative-hypnotics6. Alcohol withdrawal delirium, clinically termed delirium tremens, represents a severe, life-threatening manifestation characterized by profound autonomic hyperactivity (tachycardia, diaphoresis, hypertension), severe global confusion, and vivid, terrifying visual and tactile hallucinations11. In stark contrast to stimulant intoxication, withdrawal psychosis is driven by the sudden absence of a depressant in a profoundly neuroadapted brain. Chronic alcohol or sedative use leads to the down-regulation of inhibitory ![][image1]\-aminobutyric acid (GABA) receptors and the up-regulation of excitatory N-methyl-D-aspartate (NMDA) glutamate receptors. Upon abrupt cessation, the brain is subjected to unopposed excitatory glutamatergic transmission, resulting in a dangerous reduction in seizure thresholds, excitotoxicity, and severe psychotic delirium20.

Onset Following Medication Exposure

Iatrogenic psychosis can occur upon the initiation of a new prescription medication, a rapid dose escalation, or, less commonly, during the tapering phase6. The temporal onset varies significantly based on the medication class and the patient's individual metabolic profile. For instance, corticosteroid-induced psychosis typically manifests within three to four days of initiating high-dose therapy, though rare cases have been documented occurring within 24 hours of a single injection23. Conversely, psychosis related to long-term antimalarials, specific antimicrobial agents, or antiparkinsonian medications may present more insidiously. In these cases, steady-state concentrations gradually accumulate, or the central nervous system slowly adapts to altered receptor agonism over weeks, leading to a delayed onset of delusions or hallucinations22.

Substances Associated with Psychotic Symptoms

The etiology of substance-induced psychosis spans a broad spectrum of illicit narcotics, legally accessible psychoactive compounds, and synthetic designer drugs. The pharmacological mechanisms dictating these psychiatric reactions differ drastically across chemical classes, necessitating tailored clinical approaches.

Amphetamine-Type Stimulants and Cocaine

Stimulant psychosis serves as the archetypal pharmacological model for substance-induced persecutory delusions. Drugs such as methamphetamine, dextroamphetamine, and cocaine produce their profound behavioral effects by disrupting the normal physiological function of plasma membrane transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT)28. Cocaine acts primarily as a powerful reuptake inhibitor, blocking the clearance of these monoamines from the synaptic cleft28. In contrast, amphetamines act as substrate releasers; they enter the presynaptic terminal, disrupt vesicular storage, reverse the normal direction of transporter flux, and force massive quantities of neurotransmitters directly into the synapse1. The resultant dopaminergic flood heavily hyper-activates the brain's threat-detection, salience, and reward circuits5. Chronic users frequently experience intense paranoid delusions, overwhelmingly involving law enforcement, undercover agents, or hidden surveillance, alongside auditory, visual, and tactile hallucinations1. Tactile hallucinations, colloquially termed "cocaine bugs" or "meth mites," manifest as the vivid physical sensation of insects or foreign bodies moving beneath the skin (formication). Within a persecutory framework, these sensations are often delusionally interpreted as implanted microchips or injected poisons, frequently leading to severe self-inflicted excoriations1.

Synthetic Cathinones ("Bath Salts")

Synthetic cathinones, including 3,4-methylenedioxypyrovalerone (MDPV), mephedrone, methylone, and alpha-PVP (known colloquially as "flakka"), are synthetic ![][image2]\-ketone analogs of amphetamine derived from the naturally occurring khat plant28. These substances are notoriously potent and unpredictable. MDPV, for example, is a pure monoamine uptake inhibitor with an affinity for the dopamine transporter significantly higher than that of cocaine29. Intoxication with synthetic cathinones leads to extreme sympathetic nervous system activation, characterized by severe tachycardia, hypertension, hyperthermia, and profound physical agitation33. The neuropsychiatric profile is exceptionally severe; systematic reviews indicate that up to 38% of patients exposed to synthetic cathinones exhibit acute psychotic symptoms, characterized by profound disorientation, combativeness, and terrifying persecutory delusions33. The dangerous combination of extreme physical agitation, hallucinogenic toxicity, and psychosis frequently results in clinical conditions resembling excited delirium1. This necessitates immediate, aggressive medical stabilization to prevent lethal cardiovascular collapse, acute kidney injury, or rhabdomyolysis32.

Cannabis and Synthetic Cannabinoids

Cannabis use is a well-established environmental risk factor for both transient substance-induced psychosis and the unmasking of primary schizophrenia-spectrum disorders, particularly associated with early adolescent exposure and the heavy, frequent use of high-potency ![][image3]9-tetrahydrocannabinol (THC) products8. However, the risk of severe psychosis is exponentially magnified with the use of synthetic cannabinoid receptor agonists (SCRAs), colloquially marketed as "Spice" or "K2." Unlike phytocannabinoid THC, which acts as a partial agonist with relatively low intrinsic efficacy at the endogenous cannabinoid type-1 (CB1) receptor, many SCRAs function as full, highly potent agonists35. Utilizing sophisticated in vitro pharmacological models, such as the Black and Leff operational model, research reveals that certain SCRAs engage G-proteins and recruit ![][image2]\-arrestin with an efficacy up to 300 times greater than that of THC35. Because there is virtually no receptor reserve protecting the central nervous system from this extreme overstimulation, SCRAs induce profound disruptions in glutamate and GABA release within the prefrontal cortex and hippocampus36. This massive CB1 receptor activation translates clinically to severe psychotomimetic effects, including intense dissociation, catatonia, acute paranoia, and persistent psychotic states that frequently require prolonged inpatient psychiatric management36.

Hallucinogens and Dissociatives

Classical hallucinogens (e.g., LSD, psilocybin, mescaline) act primarily as 5-HT2A receptor agonists, inducing profound perceptual distortions, synesthesia, and altered sensory processing. While typically transient, these experiences can occasionally precipitate acute psychotic reactions or prolonged hallucinogen persisting perception disorder, particularly in vulnerable individuals30. Dissociative anesthetics, such as phencyclidine (PCP) and ketamine, act as non-competitive NMDA receptor antagonists30. Intoxication with these agents produces a severe, schizophrenia-like state characterized by delusions, hallucinations, prominent negative symptoms, and profound dissociation from reality. Psychosis induced by PCP can persist for days or even weeks following cessation due to its complex lipophilic pharmacokinetics, severely complicating the acute differential diagnosis30.

Medications and Medical Treatments Precipitating Psychosis

Iatrogenic psychosis occurs when prescribed medical treatments induce hallucinations and delusions in vulnerable individuals. The rapid recognition of medication-induced psychotic disorder is paramount for patient safety, as the primary treatment intervention involves the prompt tapering, cessation, or substitution of the offending pharmacological agent41.

Corticosteroids

Corticosteroids (e.g., prednisone, dexamethasone, hydrocortisone) are essential anti-inflammatory and immunosuppressive agents utilized across diverse medical disciplines, but they are frequently associated with profound neuropsychiatric complications. The incidence of severe psychiatric events, including steroid-induced psychosis (SIP), is estimated at 5% to 6%, with the risk scaling in a highly dose-dependent manner23. Doses exceeding 40 mg/day of prednisone (or its equivalent) substantially increase the risk of psychiatric adverse effects23. The pathophysiology involves the severe disruption of the hypothalamic-pituitary-adrenal (HPA) axis. Exogenous glucocorticoids impair natural negative feedback loops, creating a systemic environment akin to Cushing's syndrome23. Additionally, elevated glucocorticoid levels directly enhance dopamine activity in the mesolimbic system and disrupt serotonin and glutamate homeostasis, directly facilitating the onset of mania, delusions, and hallucinations23. Furthermore, chronic exposure to corticosteroids is associated with measurable decreases in hippocampal volume, contributing to long-term cognitive and mood disturbances23. Symptoms generally emerge within the first week of therapy and usually resolve following strict dose reduction; however, severe cases characterized by violent agitation or suicidal ideation may require short-term adjunctive treatment with low-dose atypical antipsychotics (e.g., olanzapine, risperidone)24.

Dopamine Agonists

Dopamine agonists, such as pramipexole, ropinirole, and rotigotine, are foundational pharmacotherapies in the management of Parkinson's disease (PD) and severe restless legs syndrome27. These agents are designed to bypass the degenerating presynaptic nigrostriatal neurons to directly stimulate post-synaptic D2, D3, and D4 receptors46. Pramipexole, in particular, exhibits a highly selective, seven-fold higher affinity for the D3 receptor, which is densely localized in the nucleus accumbens48. While highly effective for restoring motor function and sometimes utilized off-label for treatment-resistant bipolar depression, the direct, unbuffered stimulation of mesolimbic dopamine receptors carries significant psychiatric risks27. Common adverse effects include severe impulse control disorders (e.g., pathological gambling, hypersexuality, compulsive shopping) and, critically, visual hallucinations and paranoid psychosis27. The occurrence of psychosis in patients receiving dopamine agonists requires a delicate clinical balance. Management often necessitates the careful reduction of the total dopaminergic load or the cautious introduction of an atypical antipsychotic with a lower propensity for worsening parkinsonian motor symptoms, such as clozapine or quetiapine48.

Antimicrobials: Fluoroquinolones and Beta-Lactams

Antibiotic-induced encephalopathy and psychosis are under-recognized but severe clinical entities. Fluoroquinolones (e.g., ciprofloxacin, ofloxacin, levofloxacin) are broad-spectrum antimicrobials associated with severe central nervous system toxicities, ranging from agitated delirium and insomnia to acute organic psychosis and seizures26. The underlying mechanism of fluoroquinolone-induced neurotoxicity relates to their structural similarity to ![][image1]\-aminobutyric acid (GABA)20. Fluoroquinolones competitively inhibit the binding of GABA to the GABA-A receptor complex, thereby stripping the CNS of its primary inhibitory tone and precipitating a state of profound neuronal hyperexcitability20. Furthermore, these agents may upregulate glutamatergic transmission via NMDA receptor activation, exacerbating the risk of acute psychosis20. Similarly, beta-lactam antibiotics, particularly cefepime, can cause severe encephalopathy and nonconvulsive status epilepticus by blocking the postsynaptic GABA-A receptor20. These severe neuropsychiatric reactions are highly idiosyncratic but appear more frequently in the elderly, patients with pre-existing psychiatric illnesses, and individuals with impaired renal function, which leads to the toxic accumulation of the unmetabolized drug crossing the blood-brain barrier21.

Anticholinergic Agents

Anticholinergic medications, such as benztropine and trihexyphenidyl, are frequently utilized in psychiatry and neurology to manage drug-induced extrapyramidal symptoms and Parkinsonism54. These agents function as competitive antagonists of acetylcholine at central and peripheral muscarinic receptors54. In overdose, or occasionally at standard therapeutic doses in vulnerable populations (e.g., the elderly), anticholinergics precipitate an acute toxic syndrome characterized by severe, agitated delirium54. The central inhibition of cholinergic pathways yields a distinct neurobehavioral profile: severe restlessness, fluctuating mental status, incoherent mumbling speech, and vivid visual hallucinations, often accompanied by characteristic "picking" behaviors at imaginary objects in the air or on clothing55. This psychiatric presentation is universally accompanied by distinct peripheral anticholinergic signs: mydriasis, anhidrosis (dry skin), hyperthermia, tachycardia, and urinary retention55. Management centers on immediate discontinuation of the agent, administration of benzodiazepines for severe agitation, and, in severe, refractory cases of central toxicity, the cautious, highly monitored administration of the acetylcholinesterase inhibitor physostigmine56.

Summary of Iatrogenic Psychosis Mechanisms

The Phenomenology of Stimulant-Induced Persecution: Mechanisms of Surveillance Delusions

When patients present in acute distress with firm convictions that they are targets of elaborate government surveillance, espionage operations, or police monitoring, clinicians must understand the neuroethology underlying these specific delusions. The dopaminergic pathways of the basal ganglia—specifically the striatal patch (striosome) and matrix compartments—govern not only gross motor activity but also associative learning, habit formation, and the critical determination of environmental salience4. Under normal physiological conditions, dopamine dictates which environmental cues deserve attention and cognitive processing. Under the influence of severe acute or chronic stimulant toxicity, the massive, unremitting influx of dopamine effectively strips the brain of its ability to filter out irrelevant background information2. Consequently, a passing drone, a malfunctioning streetlamp, the routine presence of a police cruiser, or static on a cellular network are suddenly processed as highly significant, interconnected, and threatening events. This biochemical dysregulation frequently manifests in specific, observable behavioral syndromes that reinforce the architecture of persecution:

• Punding and Stereotypy: Chronic stimulant users often exhibit "punding," an intense, stereotypical motor behavior characterized by the repetitive, purposeless handling, examining, or dismantling of objects4. Within a delusional framework, this behavior manifests as exhaustive, repetitive checking. The individual may obsessively check locks, peer through blinds for hours, or completely dismantle cell phones, televisions, and smoke detectors, driven by the absolute certainty that they are searching for hidden transmitters, cameras, or espionage devices. This behavior is mediated by a profound imbalance between the medial prefrontal and sensorimotor corticobasal ganglia circuits, with specific overactivation of the mu-opioid receptor-rich patch compartment of the striatum4.
• Hypervigilance and Sleep Deprivation: Stimulants aggressively suppress normal sleep architecture. The combination of multi-day insomnia and sustained adrenergic output (tachycardia, elevated blood pressure) places the central nervous system in a perpetual, exhausting state of "fight-or-flight"2. The severe exhaustion of sleep deprivation degrades frontal lobe executive functioning, cementing the paranoid interpretations of the hypervigilant state and making logical redirection by medical staff impossible2.
• Tactile and Somatic Hallucinations: The sensation of formication—insects or foreign bodies moving beneath the skin—is heavily documented in amphetamine and cocaine toxicities1. In the context of a surveillance or espionage delusion, the patient's cognitive architecture interprets these tactile hallucinations not as insects, but as implanted microchips, tracking nodes, or nanobots deployed by government entities1. Patients may similarly develop delusions of being poisoned, interpreting the severe gastrointestinal distress or autonomic symptoms of drug toxicity as evidence of targeted chemical attacks. This frequently leads to severe self-inflicted excoriations in a desperate attempt to extract the perceived hardware or toxins1.

Toxicological Complexities: Beyond the Positive Screen

A fundamental error in emergency and psychiatric medicine is the assumption that a positive urine drug screen (UDS) definitively establishes the etiology of a psychotic episode. The interpretation of toxicological data requires an advanced understanding of analytical methodologies, cross-reactivities, and the pharmacokinetic dissonance between drug detection and acute clinical impairment.

Immunoassay Limitations and Cross-Reactivity

The initial UDS deployed in most clinical settings relies on immunoassay technology, which utilizes antibodies designed to bind to specific drug metabolites or drug classes62. While rapid, easily automated, and cost-effective, immunoassays lack high specificity and are notoriously prone to cross-reactivity, frequently resulting in false-positive results62. The amphetamine immunoassay is particularly vulnerable to false positives due to the simple phenethylamine structure shared by numerous common, benign medications. Over-the-counter nasal decongestants, herbal supplements, the antidepressant bupropion, and various beta-blockers can all trigger a presumptive positive amphetamine result, potentially leading to misdiagnosis and the wrongful attribution of psychosis to illicit drug use62. Conversely, immunoassays frequently yield false negatives for highly potent designer drugs. Synthetic cathinones and synthetic cannabinoids possess chemical structures divergent enough from classical amphetamines or THC that they completely fail to trigger standard screens, leading to a negative UDS in a profoundly intoxicated, psychotic patient34.

The Necessity of Confirmatory Testing

Because of these inherent analytical limitations, all positive immunoassay results must be considered strictly presumptive until verified by definitive, highly specific confirmatory testing, typically utilizing Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)62. Mass spectrometry isolates compounds based on their exact molecular weight and specific fragmentation patterns, allowing the laboratory to differentiate between a false positive caused by a prescribed medication and the true presence of an illicit substance64. Furthermore, advanced metabolite profiling via LC-MS/MS can differentiate between therapeutic adherence (e.g., prescribed dextroamphetamine for ADHD) and illicit consumption (e.g., clandestine methamphetamine use) by analyzing enantiomeric ratios and highly specific parent-to-metabolite degradation pathways69.

The Dissociation of Detection and Causality

Even when a positive result is definitively confirmed via mass spectrometry, clinical attribution remains highly complex. The detection window for many substances in urine vastly exceeds the duration of their psychoactive effects68. For example, the THC metabolite 11-nor-9-carboxy-THC can remain detectable in the urine of chronic, heavy cannabis users for several weeks following cessation68. Therefore, detecting cannabis metabolites in the urine of a patient experiencing acute psychosis does not guarantee that the psychosis is currently cannabis-induced. The patient may be experiencing the onset of a primary schizophrenia-spectrum illness, and the positive UDS simply reflects a baseline, non-contributory habit64. Consequently, a positive toxicology result alone does not establish causation; toxicological data must always be meticulously correlated with the clinical history, collateral information, and the temporal timeline of symptom onset.

Differential Diagnosis: Primary Psychosis vs. Substance-Induced Psychosis

Differentiating between substance-induced psychotic disorder (SIPD) and an independent, primary psychotic disorder (such as schizophrenia or bipolar disorder with psychotic features) is one of the most intellectually challenging tasks in acute psychiatry. Both conditions can present with severe paranoia, disorganized thought processes, and violent agitation, but identifying the correct etiology dictates both short-term psychopharmacologic management and long-term prognosis2.

Clinical Differentiators

While acute presentations may overlap entirely, certain phenotypic markers and historical clues suggest a substance-induced etiology:

• Rapidity of Onset and Baseline Functioning: SIPD typically features a rapid, fulminant onset (hours to days) directly correlated with a drug binge cycle or severe withdrawal. In contrast, primary psychotic illnesses often present with a gradual, insidious onset preceded by months or years of a prodromal phase characterized by social withdrawal, academic or occupational decline, and subtle behavioral shifts2.
• Nature of Hallucinations: SIPD is frequently characterized by prominent, intense visual and tactile hallucinations. Conversely, the hallmark of schizophrenia is complex, persistent, and structured auditory hallucinations (e.g., voices conversing with one another or commenting negatively on the patient's behavior)2.
• Absence of Negative Symptoms: Patients with SIPD often lack the prominent negative symptoms—such as affective flattening, avolition, alogia (poverty of speech), and profound anhedonia—that are deeply characteristic of chronic schizophrenia16.
• Insight and Resolution: In cases of SIPD, as the physiological clearance of the substance occurs and normal sleep architecture is restored, patients frequently regain insight rapidly, questioning the reality of their prior delusions (e.g., "Did that really happen?"). In primary psychotic disorders, profound anosognosia (lack of insight into the illness) persists long after acute agitation has subsided16.

Transition Rates and Longitudinal Reassessment

A critical paradigm shift in addiction psychiatry and epidemiology is the understanding that SIPD is not invariably a benign, transient, self-limiting condition. Large-scale, longitudinal national register studies demonstrate that a substantial proportion of individuals initially diagnosed with a substance-induced psychosis will subsequently transition to a diagnosis of a primary schizophrenia-spectrum disorder or bipolar disorder76. The transition risk is heavily dictated by the offending substance. Comprehensive meta-analyses and longitudinal cohort studies indicate that up to 34% to 47% of patients diagnosed with cannabis-induced psychosis, and 22% to 30% of those with amphetamine-induced psychosis, convert to a schizophrenia-spectrum diagnosis over a follow-up period of 3 to 8 years76. In contrast, the conversion rate for alcohol- or sedative-induced psychosis is significantly lower, ranging from 5% to 10%76. This alarmingly high rate of diagnostic conversion strongly supports the "vulnerability hypothesis." Psychoactive substances, particularly those that heavily and directly modulate dopamine and cannabinoid pathways, act as profound environmental stressors that unmask an underlying genetic or neurodevelopmental vulnerability to primary psychotic illness16. Therefore, any diagnosis of SIPD must be viewed as a high-risk clinical marker requiring rigorous longitudinal psychiatric tracking. Psychotic symptoms that persist beyond four to eight weeks of sustained, biochemically verified abstinence strongly suggest the evolution or unmasking of a primary psychotic disorder, requiring a transition to long-term antipsychotic therapy2.

Acute Medical Stabilization and Pharmacologic Management

The acute presentation of substance-induced psychosis, particularly involving stimulants or synthetic cathinones, represents a severe medical emergency. Patients are often highly agitated, physically combative due to terrifying persecutory delusions, and at risk for life-threatening hyperadrenergic complications such as hyperthermia, lethal cardiac arrhythmias, hypertensive crisis, and rhabdomyolysis33.

De-escalation and Environmental Control

Initial management must prioritize a low-stimulus environment. Providers should utilize non-confrontational, verbal de-escalation techniques from a safe distance, providing reassurance and empathy without challenging the patient's fixed delusional framework83. Because physical restraints can drastically exacerbate isometric muscle contraction, heat production, and the subsequent risk of rhabdomyolysis and severe hyperthermia, they should be avoided whenever possible and utilized strictly as a last resort for imminent physical safety81. Immediate physical cooling measures (e.g., ice water immersion, evaporative cooling) must be deployed if the patient presents with severe hyperthermia84.

Pharmacologic Sedation: The Role of Benzodiazepines

For acute, violent agitation driven by sympathomimetic toxicity, benzodiazepines (e.g., intravenous diazepam, lorazepam, or midazolam) are universally recommended as the first-line pharmacologic intervention81. Benzodiazepines facilitate GABAergic inhibition, which not only rapidly sedates the agitated patient but critically blunts the excessive central sympathetic outflow84. This targeted sympatholysis directly treats the underlying cardiovascular toxicity, lowers dangerously elevated blood pressure, terminates seizures, and allows the body to cool, mitigating the immediate risk of end-organ damage81.

The Cautious Application of Antipsychotics

While antipsychotics directly antagonize the hyper-dopaminergic state driving the persecutory delusions, their use in the acute, undifferentiated toxicity phase requires significant medical caution. First- and second-generation antipsychotics (e.g., haloperidol, olanzapine, droperidol) can be administered if high-dose benzodiazepines fail to achieve behavioral control, or if prominent psychotic symptoms persist post-sedation3. However, clinicians must remain highly vigilant regarding the adverse effects of antipsychotics in the setting of acute intoxication. Antipsychotics can lower the seizure threshold, precipitate acute dystonic reactions, impair central thermoregulation (drastically exacerbating hyperthermia), and cause QT-interval prolongation, which is particularly dangerous in a myocardium already stressed by stimulants3. Therefore, the use of antipsychotics is generally reserved for refractory agitation or utilized more safely in the subacute phase (days to weeks later) to manage lingering hallucinations and delusions after the acute sympathomimetic crisis has completely resolved82.

Long-Term Management: Addiction Treatment, Harm Reduction, and Social Support

Resolving the acute psychotic episode is merely the initial phase of psychiatric care. Long-term stabilization requires a highly integrated, multidisciplinary approach encompassing evidence-based addiction treatment, housing stability, and robust harm reduction strategies.

Contingency Management for Stimulant Use Disorder

While opioid use disorder is effectively managed with medications (e.g., buprenorphine, methadone), there are currently no FDA-approved pharmacotherapies for stimulant use disorder (StUD)87. Instead, the absolute gold standard of care for preventing relapse is Contingency Management (CM)87. CM is an evidence-based behavioral intervention rooted in operant conditioning. It utilizes the systemic delivery of tangible, positive reinforcement (vouchers or prizes) to immediately reward objectively verifiable target behaviors, most commonly the submission of drug-free urine samples 2 to 3 times per week87. By providing immediate, alternative rewards, CM functionally competes with and counterbalances the powerful neurobiological reinforcement loops hijacked by stimulant use87. The clinical efficacy of CM is highly dependent on protocol design, particularly the magnitude of the financial reinforcement. Low-value, token protocols (e.g., $75 total limits) often fail to alter behavior; successful models necessitate an escalating reinforcement schedule where consistent negative tests yield increasingly valuable rewards, with evidence suggesting a minimum effective budget of roughly $128 per week, or totals reaching upwards of $599 over a 24-week period88. Large-scale implementations, such as the prize-based "fishbowl" model utilized nationwide by the U.S. Department of Veterans Affairs, have demonstrated unparalleled success, not only in sustaining abstinence but in significantly reducing all-cause mortality among patients with StUD88.

Harm Reduction and Social Support Infrastructure

Because relapse is a recognized, expected component of chronic substance use disorders, tertiary prevention via harm reduction is a clinical imperative. Adhering to guidelines from the American Society of Addiction Medicine (ASAM), clinicians must proactively educate patients on overdose prevention. This includes distributing naloxone due to the frequent, lethal contamination of the illicit stimulant supply with synthetic opioids like fentanyl84. Harm reduction counseling must also explicitly address safer consumption practices (e.g., avoiding using alone, utilizing safer consumption sites to gauge substance strength), safer injection practices to prevent infectious disease transmission, and the maintenance of adequate oral hygiene and nutrition, as stimulant users are at extremely high risk for severe dental complications and malnutrition84. Furthermore, clinical recovery is intrinsically tied to the social determinants of health. Patients recovering from severe SIPD frequently experience massive social dislocation, legal consequences, and poverty. Comprehensive community health systems—such as those modeled by organizations providing holistic mental health counseling, Medication-Assisted Recovery (MAR), and intensive case management (e.g., the Pilsen Wellness Center model)—are vital92. Transitional and interim housing programs that operate on harm-reduction and trauma-informed principles (such as master-leased, scattered-site apartments) provide the physical safety, privacy, and dignity necessary for patients to stabilize cognitively, escape the environmental triggers of drug use, and engage consistently in outpatient psychiatric care95.

Clinical Vignette: The Intersection of Toxicology and Psychosis

To holistically illustrate the clinical complexities of timeline reconstruction, toxicological nuance, and diagnostic uncertainty, consider the following presentation. Mr. J., a 29-year-old software engineer, was brought to the emergency department by local law enforcement. Officers were responding to a 911 call from a residential neighborhood regarding a male attempting to violently pry open the electrical junction boxes of several homes. Upon police arrival, Mr. J. was highly agitated, combative, and claimed that the electrical boxes contained miniaturized drone relays installed by federal intelligence agents to extract intellectual property directly from his cerebral cortex. In the emergency department, Mr. J. exhibited profound hypervigilance, diaphoresis, resting tachycardia (135 bpm), and pupillary dilation. He frequently picked at his forearms, insisting that "micro-transmitters" and chemical poisons had been injected into his vasculature by an undercover agent posing as a police officer. Collateral Information and Timeline Immediate contact with Mr. J.'s partner revealed no prior psychiatric history of schizophrenia or bipolar disorder. However, the partner noted that Mr. J. had been under immense occupational stress and had begun isolating himself in his home office three weeks prior. He had not slept in the past four days, pacing the house and repetitively checking the locks on all doors and windows (punding/stereotypy). Importantly, the partner reported that Mr. J. was prescribed dextroamphetamine for ADHD but had recently begun purchasing "hyper-focus supplements" online to meet project deadlines. The partner also noted that Mr. J. had received a routine traffic citation for speeding five days ago, an event that deeply unsettled him. Toxicological Interpretation An initial point-of-care immunoassay UDS returned a presumptive positive result for amphetamines and negative for all other substances. While the clinical team initially assumed dextroamphetamine toxicity, the extreme severity of the autonomic instability and the bizarre, highly structured nature of the persecutory psychosis raised clinical suspicion. A comprehensive confirmatory LC-MS/MS panel was ordered to definitively identify the circulating compounds. The mass spectrometry confirmed therapeutic levels of dextroamphetamine, but crucially, it also detected alpha-PVP (a synthetic cathinone/"flakka"), which had cross-reacted minimally with the immunoassay but was the primary driver of the clinical presentation. The online "focus supplements" were, in reality, illicitly manufactured synthetic cathinones. Clinical Course and Diagnostic Nuance Mr. J. was immediately placed in a low-stimulus environment. To manage the acute sympathomimetic toxicity, prevent cardiovascular collapse, and mitigate the violent agitation without using restraints, he received titrated doses of intravenous diazepam. The benzodiazepine successfully lowered his heart rate, blunted the sympathetic outflow, and facilitated much-needed sleep. Upon awakening 16 hours later, Mr. J. remained highly suspicious but was no longer acutely agitated. When questioned about the federal agents, he referenced the traffic stop from five days prior as "the moment they marked me for capture." The clinical team carefully documented this factual interaction with law enforcement in the chart, explicitly separating the reality of the routine speeding ticket from the psychotic elaboration that the officer had implanted tracking software in his vehicle and poisoned his water supply. The team provided empathetic reassurance without ever validating the ongoing surveillance claims. By hospital day four, with continued abstinence and the restoration of circadian rhythms, Mr. J.'s formication ceased entirely, and his insight began to return. He expressed profound embarrassment regarding his actions and questioned the reality of the drone relays. Because his psychosis resolved completely with the clearance of the synthetic cathinone and the resumption of sleep, a diagnosis of Synthetic Cathinone-Induced Psychotic Disorder was established. However, understanding the alarmingly high rate of diagnostic conversion to primary schizophrenia-spectrum disorders, the psychiatric team arranged for intensive outpatient follow-up. Mr. J. was linked with a community wellness center providing cognitive-behavioral therapy, a high-value contingency management program to address the emerging stimulant misuse, and scheduled psychiatric reassessments at 3 and 6 months to aggressively monitor for any insidious re-emergence of primary psychotic symptoms.

Works cited

1. Stimulant psychosis \- Wikipedia, https://en.wikipedia.org/wiki/Stimulant\_psychosis
2. Stimulant Psychosis vs. Mental Illness Guide \- Red Rock Recovery Center, https://www.redrockrecoverycenter.com/rehab-blog/stimulant-psychosis-vs-mental-illness-how-to-tell-the-difference/
3. Emergency department management of acute agitation in the reproductive age female and pregnancy \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10925524/
4. Key role of striatal cholinergic interneurons in processes leading to arrest of motor stereotypies | Brain | Oxford Academic, https://academic.oup.com/brain/article/134/1/110/291548
5. The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3931688/
6. Substance-Induced Psychosis DSM-5 Diagnosis Guidelines \- Carepatron, https://www.carepatron.com/files/substance-induced-psychosis-dsm-5-diagnosis-guidelines.pdf
7. Drug-induced psychosis and schizophrenia: How do they differ? \- Medical News Today, https://www.medicalnewstoday.com/articles/drug-induced-psychosis-vs-schizophrenia
8. Cannabis-Induced Psychotic Disorder and Schizophrenia Diagnostic Comparison Honors Thesis Defense, https://scholarworks.wmich.edu/cgi/viewcontent.cgi?filename=2\&article=4755\&context=honors\_theses\&type=additional
9. Problematic diagnosis of substance-induced disorders in ICD-11 \- PMC \- NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC11457132/
10. Problematic diagnosis of substance-induced disorders in ICD-11 \- ResearchGate, https://www.researchgate.net/publication/384129813\Problematic\diagnosis\of\substance-induced\disorders\in\_ICD-11
11. ICD-11 Criteria for Disorders Due to Substance use or Addictive Behaviours (BlockL1‑6C4), https://www.mrcpsych.uk/2022/05/icd-11-criteria-for-disorders-due-to.html
12. 6C4C.Z \- Disorders due to use of MDMA or related drugs, including MDA, unspecified | ICD-11 2026 \- AutoICD API, https://autoicdapi.com/reference/icd-11/6C4C.Z
13. Problematic diagnosis of substance-induced disorders in ICD-11 | European Psychiatry, https://www.cambridge.org/core/journals/european-psychiatry/article/problematic-diagnosis-of-substanceinduced-disorders-in-icd11/EF039AC6B5E7968105185167273D654D
14. Problematic diagnosis of substance-induced disorders in ICD-11 \- UTUPub, https://www.utupub.fi/bitstream/handle/10024/189958/problematic-diagnosis-of-substance-induced-disorders-in-icd-11.pdf?sequence=1\&isAllowed=y
15. Cocaine addiction: From habits to stereotypical-repetitive behaviors and punding | Request PDF \- ResearchGate, https://www.researchgate.net/publication/5475067\Cocaine\addiction\From\habits\to\stereotypical-repetitive\behaviors\and\_punding
16. Substance-induced psychosis vs schizophrenia explained with key differences, https://www.brightquest.com/blog/substance-induced-psychosis-vs-schizophrenia/
17. Drug-Induced Psychosis: Symptoms, Duration, and Treatment \- Soberman's Estate, https://www.sobermansestate.com/blog/drug-induced-psychosis-symptoms-duration-and-treatment
18. Development of stereotyped behaviors during prolonged escalation of methamphetamine self-administration in rats \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3586274/
19. Substance-induced psychotic disorder \- Comorbidity Guidelines, https://comorbidityguidelines.org.au/what-are-substance-induced-disorders/substanceinduced-psychotic-disorder
20. The Effect of Antibiotics on the Nervous System: Importance for Anesthesiology and Intensive Care \- MDPI, https://www.mdpi.com/2079-6382/14/6/622
21. Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11513374/
22. Adverse psychiatric effects of non-psychotropic medications | BJPsych Advances, https://www.cambridge.org/core/journals/bjpsych-advances/article/adverse-psychiatric-effects-of-nonpsychotropic-medications/BDAC530921AC6D07765AF83BB4124C42
23. Steroid Induced Psychosis: Current Understanding and Novel Approaches to Management, https://ijprajournal.com/issue\_dcp/Steroid%20Induced%20Psychosis%20Current%20Understanding%20and%20Novel%20Approaches%20to%20Management.pdf
24. Pharmacological Management of Steroid-Induced Psychosis: A Review of Patient Cases, https://pmc.ncbi.nlm.nih.gov/articles/PMC7953074/
25. Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications \- MDPI, https://www.mdpi.com/2079-9721/12/12/300
26. Commonly Used Drugs for Medical Illness and the Nervous System | Continuum, https://continuum.aan.com/doi/10.1212/CON.0000000000000854
27. Ropinirole \- StatPearls \- NCBI Bookshelf \- NIH, https://www.ncbi.nlm.nih.gov/books/NBK554532/
28. Synthetic Cathinones and amphetamine analogues: What's the rave about? \- PMC \- NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC5556313/
29. Neuropharmacology of Synthetic Cathinones \- PMC \- NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC7257813/
30. Substance-Induced Psychosis: Symptoms, Causes, and Treatment, https://americanaddictioncenters.org/health-complications-addiction/drug-induced-psychosis
31. Psychoactive Bath Salts and Neurotoxicity Risk \- PMC \- NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC7227911/
32. Bath Salts: Effects, Withdrawal & Treatment \- Empowered Recovery Center, https://www.empoweredrecoverycenter.com/addiction/synthetic-drugs/bath-salts/
33. Bath Salts Effects: How Cathinones Affect the Brain & Body?, https://thoroughbredbhc.com/blog/bath-salts-effects/
34. Bath Salts or Synthetic Cathinones | California Poison Control System, https://calpoison.org/blog/bath-salts-or-synthetic-cathinones
35. In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6965679/
36. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin and glutamate systems \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6419500/
37. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC4582439/
38. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor \- ACS Publications, https://pubs.acs.org/doi/10.1021/acschemneuro.3c00530
39. In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids \- bioRxiv, https://www.biorxiv.org/content/10.1101/385583v1.full-text
40. The Rise in Synthetic Cannabinoids and Cathinones \- Psychiatric Times, https://www.psychiatrictimes.com/view/synthetic-cannabinoids-cathinones
41. Substance- or Medication-Induced Psychotic Disorder \- Psychiatry \- MSD Manuals, https://www.msdmanuals.com/professional/psychiatric-disorders/schizophrenia-and-related-disorders/substance-or-medication-induced-psychotic-disorder
42. Corticosteroid psychosis: Stop therapy or add psychotropics?, https://cdn-uat.mdedge.com/files/s3fs-public/Document/September-2017/0901CP\_MedPsych.pdf
43. Nonpsychotropic Medication-Induced Psychosis \- U.S. Pharmacist, https://www.uspharmacist.com/article/nonpsychotropic-medicationinduced-psychosis
44. Corticosteroid-induced manic and/or psychotic symptoms: a systematic review \- PMC \- NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC12321511/
45. Corticosteroid-Induced Psychiatric Symptoms | Palliative Care Network of Wisconsin, https://www.mypcnow.org/fast-fact/corticosteroid-induced-psychiatric-symptoms/
46. The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine | Request PDF \- ResearchGate, https://www.researchgate.net/publication/369430099\The\complex\molecular\pharmacology\of\the\dopamine\D2\receptor\Implications\for\pramipexole\ropinirole\and\_rotigotine
47. Dopamine agonist \- Wikipedia, https://en.wikipedia.org/wiki/Dopamine\_agonist
48. Mechanism of Parkinson's Disease Drugs \- Encyclopedia.pub, https://encyclopedia.pub/entry/20237
49. Hidden Gems: Pramipexole Part I | CARLAT PUBLISHING, https://www.thecarlatreport.com/blogs/2-the-carlat-psychiatry-podcast/post/5844-hidden-gems-pramipexole-part-i
50. Dopamine Receptor Inhibitors \- Selleck Chemicals, https://www.selleckchem.com/Dopamine-receptor.html?page=others
51. Drug-induced hallucination: a case/non case study in the French Pharmacovigilance Database, https://scielo.isciii.es/scielo.php?script=sci\_arttext\&pid=S0213-61632015000100002
52. High Dose Ofloxacin-induced Bimodal Hallucinations in a 4 Years Old Child, https://www.cpn.or.kr/journal/view.html?doi=10.9758/cpn.2017.15.4.416
53. Fluoroquinolone Induced Neurotoxicity: A Review \- Journal of Advanced Pharmacy Education and Research, https://japer.in/storage/models/article/XGMyxG5Zs13aIXBUyjaqefsw3D4LgVS5U1762EbiS22kAfKYpDfmJVrOT7b5/fluoroquinolone-induced-neurotoxicity-a-review.pdf
54. Benztropine \- StatPearls \- NCBI Bookshelf \- NIH, https://www.ncbi.nlm.nih.gov/books/NBK560633/
55. Anticholinergic Medications \- StatPearls \- NCBI Bookshelf \- NIH, https://www.ncbi.nlm.nih.gov/books/NBK555893/
56. Clinical Practice Guidelines : Anticholinergic syndrome \- The Royal Children's Hospital, https://www.rch.org.au/clinicalguide/guideline\index/Anticholinergic\_syndrome/
57. Anticholinergic \- Wikipedia, https://en.wikipedia.org/wiki/Anticholinergic
58. Benztropine toxicity \- LITFL, https://litfl.com/benztropine-toxicity/
59. STRIATAL PATCH COMPARMTENT LESIONS ALTER METHAMPHETAMINE-INDUCED BEHAVIOR AND IMMEDIATE EARLY GENE EXPRESSION IN THE STRIATUM, SUBSTANTIA NIGRA AND FRONTAL CORTEX \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3757105/
60. Neurologic manifestations of chronic methamphetamine abuse \- PMC \- NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC3148451/
61. What Is Stimulant-Induced Psychosis? \- Gateway Foundation, https://www.gatewayfoundation.org/blog/stimulant-induced-psychosis/
62. False-Positive Interferences of Common Urine Drug Screen Immunoassays \- Ovid, https://www.ovid.com/journals/joat/fulltext/10.1093/jat/bku075\~false-positive-interferences-of-common-urine-drug-screen
63. Clinical Interpretation of Urine Drug Tests \- Ohio.gov, https://dam.assets.ohio.gov/image/upload/opd.ohio.gov/Law%20Library/Training/OPD%20Training%20Materials/2021%20Virtual%20Legal%20Summit/November/Common\Errors\In\Drug\Testing\_Mayo-2017.pdf
64. Urine Drug Tests: Ordering and Interpretation | AFP \- AAFP, https://www.aafp.org/afp/2019/0101/p33
65. Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC7055671/
66. CP.MP.208 Drugs of Abuse: Presumptive Testing \- Home State Health, https://www.homestatehealth.com/content/dam/centene/home-state-health/pdfs/CpMp208DrugAbusPresmtveTst.pdf
67. What common substances can cause false positives on urine screens for drugs of abuse?, https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/5510JFP\_ClinicalInquiries1.pdf
68. ADLM Guidance Document on Laboratory Testing for Drugs of Misuse to Support the Emergency Department \- Oxford Academic, https://academic.oup.com/jalm/article/11/1/155/8414133
69. Differentiation of Therapeutic and Illicit Drug Use via Metabolite Profiling \- Semantic Scholar, https://pdfs.semanticscholar.org/0771/b70ca4ecafaaacd062d3b556a429e8127828.pdf
70. Differentiation of Therapeutic and Illicit Drug Use via Metabolite Profiling \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12654502/
71. ADLM guidance document on laboratory testing for drugs of misuse to support the emergency department | myadlm.org, https://myadlm.org/science-and-research/academy-guidance/testing-for-drugs-of-misuse-to-support-the-emergency-department
72. Substance-Induced Psychosis: Diagnostic Challenges and Phenomenological Insights, https://www.mdpi.com/2673-5318/5/4/52
73. Understanding the Complex Interplay of Substance Use and Psychosis | Skyland Trail, https://www.skylandtrail.org/understanding-the-complex-interplay-of-substance-use-and-psychosis/
74. Substance-Induced Psychotic Disorder (SIPD): Symptoms & Treatment \- Change Direction, https://www.changedirection.org/conditions/substance-induced-psychotic-disorder
75. Schizophrenia & Substance Use: Telling Them Apart | Bliss Recovery LA, https://blissrecoveryla.com/blog/schizophrenia-and-substance-use-differentiating-symptoms-from-substance-induced-psychosis/
76. Substance-Induced Psychoses Converting Into Schizophrenia: A Register-Based Study of 18,478 Finnish Inpatient Cases \- Psychiatrist.com, https://www.psychiatrist.com/jcp/substance-induced-psychoses-converting-schizophrenia/
77. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC7147575/
78. Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder | American Journal of Psychiatry, https://www.psychiatryonline.org/doi/full/10.1176/appi.ajp.22010076
79. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis \- PubMed, https://pubmed.ncbi.nlm.nih.gov/29179576/
80. Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study | Psychological Medicine, https://www.cambridge.org/core/journals/psychological-medicine/article/risk-of-transition-to-schizophrenia-following-first-admission-with-substanceinduced-psychotic-disorder-a-populationbased-longitudinal-cohort-study/60E022FAFCBF699311471405EC4561CF
81. Amphetamines Overdose \- The Recovery Village Ridgefield, https://www.ridgefieldrecovery.com/drugs/amphetamines/amphetamine-overdose/
82. Pharmacotherapy treatment of stimulant use disorder \- PMC \- NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC8582769/
83. Management of Acute Presentations Related to Methamphetamine Use Clinical Guideline for Adults | SA Health, https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/resources/policies/management+of+acute+presentations+related+to+methamphetamine+use+clinical+guideline+for+adults
84. S'now Problem: Keep your Cool when Stimulants turn up the Speed \- EMOttawa Blog, https://emottawablog.com/2024/10/snow-problem-keep-your-cool-when-stimulants-turn-up-the-speed/
85. The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11105801/
86. Benztropine (Cogentin) \- Pharmacology for Medicine \- Picmonic, https://www.picmonic.com/pathways/medicine/courses/standard/pharmacology-160/cholinergic-receptor-pharmacology-36139/benztropine-cogentin\_2019
87. Implementing an evidence-based prize contingency management protocol for stimulant use, https://pmc.ncbi.nlm.nih.gov/articles/PMC10330855/
88. Guest Editorial — Contingency Management Saves Lives: From Evidence to Action, http://medresearch.umich.edu/department-news/guest-editorial-contingency-management-saves-lives-evidence-action
89. Contingency management for stimulant use disorder and association with mortality: a cohort study \- PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12872285/
90. Contingency Management for the Treatment of Substance Use Disorders: Enhancing Access, Quality, and Program Integrity for an Evidence-Based Intervention, https://aspe.hhs.gov/sites/default/files/documents/a0cc6fcdb2968be95f60bb1c2c94eb70/contingency-management-sub-treatment.pdf
91. Addiction Messenger Feature Article July 2025, https://attcnetwork.org/addiction-messenger-feature-article-july-2025/
92. 708 Mental Health Board \- The Town of Cicero, https://thetownofcicero.com/community/community-mental-health-board/
93. Substance Use Recovery \- Chicago \- Pilsen Wellness Center, https://www.pilsenwellnesscenter.org/en/services/substanceUseRecovery
94. About \- Pilsen Wellness Center, https://www.pilsenwellnesscenter.org/en/about
95. Transitional and permanent housing in Chicago and Waukegan, Illinois \- Ascension, https://healthcare.ascension.org/specialty-care/behavioral-mental-health/why-ascension/ilchi-chicago-il-housing-and-health-alliance
96. Temporary housing for vulnerable individuals and families experiencing homelessness \- BEDS Plus, https://beds-plus.org/interim-housing-services/

[image1]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAwAAAAcCAYAAABVo158AAAAmElEQVR4XmNgGAWDCUhCcS0QVwIxNxSDACcQa0IxGMgD8UUo3gbEd4B4AhQzArEfENtAMXkaSoBYFYpBAOSEXihWAeIyqBgIgwHMrcjAE4pBfgLZQBAYQ/FWIBZHk8MKyNbQygDxOEEACxWQP4gCWVBsii6BC5CkgQOIp0KxNJocVgAKlXYoZkGTwwqYgZgLiokCJGsY9gAAhd4Yyig9lP8AAAAASUVORK5CYII=>

[image2]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA0AAAAbCAYAAACnZAX6AAAA30lEQVR4Xu3SPQtBURzH8b9QBsVgkUFGixh4ASykTAZlNDDIw6TMDJSFzQuwmAzegbJ7RX5/53d1H6Tb2ZRvfZZz7zn3nNsR+cmi0KY9NCFCH0vBGkqkC2yhR4F0pRFUfOML2FGgAizFu40YnOTLl6wmtcQcugFdmsMB4hRIz1OGlZi/pi4wc7/klCTdWsL3rAp3yNA7q0lFGrgHmU56QJbedUhvgL8xXMXswLML59B911ieblBzjb/Ss2zoCBMxq5/JfzteWU3SHzAkLS1moa/pLahT6KaQo9BZTfpn2xNOUyU6upZZmwAAAABJRU5ErkJggg==>

[image3]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABEAAAAaCAYAAABRqrc5AAAAxElEQVR4Xu3SsQpBYRjG8U8xKGUzMZi5AatSLkBxA2KwuQGJTSaL0aRchYtQbsBmsCmDeB7nyTnnQ+erY/z+9Zvezlvn7TPG51pGptC0Zs7V5Aw7yMXHbo1lA1doxMdupV5SgZmU4QgrE97JqT60hE3gAnVJrARLyAurwskEyyixvyzpSjTegTfhIuLSrxVkAUVrxngL3oVG1uxdWwb2QGVhKwcT/PZHqZfwSa9lCJ0f5nKH3uvLSHyNN3k42pvwjj6fU0/6szKnOTZrtgAAAABJRU5ErkJggg==>